Sarepta Therapeutics Inc
XBER:AB3A
Sarepta Therapeutics Inc
XBER:AB3A
Price:
18.185
EUR
Market Closed
Market Cap:
€1.1B
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
S
|
Sarepta Therapeutics Inc
XBER:AB3A
|
US |
|
Masivo Silver Corp
XTSX:MASS
|
CA |
|
S
|
Simon Property Group Inc
LSE:0L6P
|
US |
|
Dana Brata Luhur Tbk PT
IDX:TEBE
|
ID |
|
J
|
Jiangxi Copper Co Ltd
XMUN:JIX
|
CN |
|
R
|
Rio Tinto Ltd
XMUN:CRA1
|
AU |
|
C
|
Cincinnati Financial Corp
DUS:CCJ
|
US |
|
Carrefour SA
F:CAR1
|
FR |
|
iQ International AG
F:IQL
|
CH |
|
C
|
Close Brothers Group PLC
DUS:CS3
|
UK |
|
H
|
Heidelberg Pharma AG
XBER:HPHA
|
DE |
|
C
|
CVR Energy Inc
XBER:FL9
|
US |
|
C
|
China Life Insurance Co Ltd
F:CLF
|
CN |
|
F
|
Fastenal Co
SWB:FAS
|
US |
|
R
|
Rederi Gotland AB
STO:GOTL A
|
SE |
|
I
|
Inspire Medical Systems Inc
F:2DR
|
US |
|
T
|
Transurban Group
OTC:TRAUF
|
AU |
|
A
|
Autodesk Inc
XETRA:AUD
|
US |
Wall St Price Targets
AB3A Price Targets Summary
Sarepta Therapeutics Inc
Sarepta Therapeutics Inc
Wall Street analysts forecast AB3A stock price to rise over the next 12 months.
According to Wall Street analysts, the average 1-year price target for AB3A is 22.023 EUR with a low forecast of 4.919 EUR and a high forecast of 38.863 EUR.
Lowest Forecast
Price Target
4.919
EUR
73% Downside
Average Forecast
Price Target
22.023
EUR
21% Upside
Highest Forecast
Price Target
38.863
EUR
114% Upside
Why do you have more estimates than other sites?
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is AB3A's stock price target?
Price Target
22.023
EUR
22.023
EUR
According to Wall Street analysts, the average 1-year price target for AB3A is 22.023 EUR with a low forecast of 4.919 EUR and a high forecast of 38.863 EUR.
What is the Revenue forecast for Sarepta Therapeutics Inc?
Projected CAGR
-3%
-3%
Over the last 14 years, the compound annual growth rate for Revenue has been 32%. The projected CAGR for the next 8 years is -3%.
